Yael P Mosse

Summary

Affiliation: The Children's Hospital of Philadelphia
Country: USA

Publications

  1. ncbi request reprint Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study
    Yael P Mosse
    Division of Oncology and Center for Childhood Cancer Research, Children s Hospital of Philadelphia, Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Clin Cancer Res 18:6058-64. 2012
  2. pmc Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study
    Yael P Mosse
    Division of Oncology and Center for Childhood Cancer Research, Children s Hospital of Philadelphia, and Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA Electronic address
    Lancet Oncol 14:472-80. 2013
  3. doi request reprint Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project
    Yael P Mosse
    Division of Oncology, Children s Hospital of Philadelphia and Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania
    Pediatr Blood Cancer 61:627-35. 2014
  4. pmc STAC: A method for testing the significance of DNA copy number aberrations across multiple array-CGH experiments
    Sharon J Diskin
    Division of Oncology, Children s Hospital of Philadelphia, Pennsylvania 19104, USA
    Genome Res 16:1149-58. 2006
  5. ncbi request reprint Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression
    Yael P Mosse
    Division of Oncology, Children s Hospital of Philadelphia, and Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Genes Chromosomes Cancer 46:936-49. 2007
  6. pmc Chromosome 6p22 locus associated with clinically aggressive neuroblastoma
    John M Maris
    Division of Oncology and the Center for Childhood Cancer Research, Children s Hospital of Philadelphia, Philadelphia, PA 19104 4318, USA
    N Engl J Med 358:2585-93. 2008
  7. pmc Genomic copy number determination in cancer cells from single nucleotide polymorphism microarrays based on quantitative genotyping corrected for aneuploidy
    Edward F Attiyeh
    Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, and Abramson Family Cancer Research Institute, Philadelphia, Pennsylvania 19104 4318, USA
    Genome Res 19:276-83. 2009
  8. ncbi request reprint Evidence for a hereditary neuroblastoma predisposition locus at chromosome 16p12-13
    John M Maris
    Department of Pediatrics, University of Pennsylvania School of Medicine and Children s Hospital of Philadelphia, Abramson Pediatric Research Center, Philadelphia, Pennsylvania 19104 4318, USA
    Cancer Res 62:6651-8. 2002
  9. ncbi request reprint Chromosome 1p and 11q deletions and outcome in neuroblastoma
    Edward F Attiyeh
    Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, PA 19104 4318, USA
    N Engl J Med 353:2243-53. 2005
  10. doi request reprint Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial
    Steven G DuBois
    Department of Pediatrics, UCSF School of Medicine, San Francisco, California 94143, USA
    Clin Cancer Res 18:2679-86. 2012

Research Grants

Collaborators

Detail Information

Publications15

  1. ncbi request reprint Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study
    Yael P Mosse
    Division of Oncology and Center for Childhood Cancer Research, Children s Hospital of Philadelphia, Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Clin Cancer Res 18:6058-64. 2012
    ..We conducted a phase I trial in children with refractory/recurrent solid tumors to define the maximum-tolerated dose, toxicities, and pharmacokinetic properties of MLN8237...
  2. pmc Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study
    Yael P Mosse
    Division of Oncology and Center for Childhood Cancer Research, Children s Hospital of Philadelphia, and Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA Electronic address
    Lancet Oncol 14:472-80. 2013
    ..We aimed to determine the safety, recommended phase 2 dose, and antitumour activity of crizotinib in children with refractory solid tumours and anaplastic large-cell lymphoma...
  3. doi request reprint Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project
    Yael P Mosse
    Division of Oncology, Children s Hospital of Philadelphia and Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania
    Pediatr Blood Cancer 61:627-35. 2014
    ..Our goal was to determine if an optimal age cut-off exists that defines indolent disease and if accepted prognostic factors and treatment approaches are applicable to older children...
  4. pmc STAC: A method for testing the significance of DNA copy number aberrations across multiple array-CGH experiments
    Sharon J Diskin
    Division of Oncology, Children s Hospital of Philadelphia, Pennsylvania 19104, USA
    Genome Res 16:1149-58. 2006
    ..We conclude that STAC is a powerful tool for identifying nonrandom genomic amplifications and deletions across multiple experiments. A Java version of STAC is freely available for download at http://cbil.upenn.edu/STAC...
  5. ncbi request reprint Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression
    Yael P Mosse
    Division of Oncology, Children s Hospital of Philadelphia, and Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Genes Chromosomes Cancer 46:936-49. 2007
    ..DNA signature patterns embed important prognostic information in diagnostic neuroblastoma samples, and can identify candidate cancer-related genes...
  6. pmc Chromosome 6p22 locus associated with clinically aggressive neuroblastoma
    John M Maris
    Division of Oncology and the Center for Childhood Cancer Research, Children s Hospital of Philadelphia, Philadelphia, PA 19104 4318, USA
    N Engl J Med 358:2585-93. 2008
    ..Neuroblastoma is a malignant condition of the developing sympathetic nervous system that most commonly affects young children and is often lethal. Its cause is not known...
  7. pmc Genomic copy number determination in cancer cells from single nucleotide polymorphism microarrays based on quantitative genotyping corrected for aneuploidy
    Edward F Attiyeh
    Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, and Abramson Family Cancer Research Institute, Philadelphia, Pennsylvania 19104 4318, USA
    Genome Res 19:276-83. 2009
    ....
  8. ncbi request reprint Evidence for a hereditary neuroblastoma predisposition locus at chromosome 16p12-13
    John M Maris
    Department of Pediatrics, University of Pennsylvania School of Medicine and Children s Hospital of Philadelphia, Abramson Pediatric Research Center, Philadelphia, Pennsylvania 19104 4318, USA
    Cancer Res 62:6651-8. 2002
    ..Taken together, these data suggest that a hereditary neuroblastoma predisposition gene (HNB1) is located at 16p12-13 and that disruption of this gene may contribute to the pathogenesis of nonfamilial neuroblastomas...
  9. ncbi request reprint Chromosome 1p and 11q deletions and outcome in neuroblastoma
    Edward F Attiyeh
    Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, PA 19104 4318, USA
    N Engl J Med 353:2243-53. 2005
    ..Neuroblastoma is a childhood cancer with considerable morbidity and mortality. Tumor-derived biomarkers may improve risk stratification...
  10. doi request reprint Phase I study of vincristine, irinotecan, and ¹³¹I-metaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: a new approaches to neuroblastoma therapy trial
    Steven G DuBois
    Department of Pediatrics, UCSF School of Medicine, San Francisco, California 94143, USA
    Clin Cancer Res 18:2679-86. 2012
    ..Irinotecan is a known radiosensitizer with activity in neuroblastoma. This phase I study aimed to determine the recommended phase 2 dose of MIBG together with fixed doses of vincristine and irinotecan...
  11. pmc Targeting ALK in neuroblastoma--preclinical and clinical advancements
    Erica L Carpenter
    Division of Oncology and Center for Childhood Cancer Research, Children s Hospital of Philadelphia, 3501 Civic Center Boulevard, Philadelphia, PA 19104, USA
    Nat Rev Clin Oncol 9:391-9. 2012
    ....
  12. doi request reprint Safety and efficacy of tandem 131I-metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma
    Kelsey Johnson
    University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    Pediatr Blood Cancer 57:1124-9. 2011
    ..The goal of this study was to determine the safety and efficacy of early (<100 days) second (131) I-MIBG treatment following an effective initial treatment...
  13. pmc Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma
    Scott C Bresler
    Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104 6059, USA
    Sci Transl Med 3:108ra114. 2011
    ..Thus, this effect should be surmountable with higher doses of crizotinib and/or with higher-affinity inhibitors...
  14. pmc Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity
    Kristopher R Bosse
    Division of Oncology and Center for Childhood Cancer Research, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
    Cancer Res 72:2068-78. 2012
    ..The interaction of BARD1β with the Aurora family of kinases lends strong support to the ongoing work to develop Aurora kinase inhibitors for clinically aggressive neuroblastoma...
  15. doi request reprint Inhibition of ALK signaling for cancer therapy
    Yael P Mosse
    Division of Oncology and Center for Childhood Cancer Research, Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104 4318, USA
    Clin Cancer Res 15:5609-14. 2009
    ..The identification of the downstream effector pathways controlled by ALK should pave the way for the rational design of ALK-inhibition therapies for the treatment of a subset of human cancers that harbor ALK aberrations...

Research Grants3

  1. Targeting Oncogenic ALK Signaling in Neuroblastoma
    Yael Mosse; Fiscal Year: 2009
    ..This project will result in important steps forward in developing rational therapeutic strategies aimed at inhibiting ALK- mediated signaling for this often-devastating childhood cancer. ..
  2. Targeting Oncogenic ALK Signaling in Neuroblastoma
    Yael P Mosse; Fiscal Year: 2010
    ..This project will result in important steps forward in developing rational therapeutic strategies aimed at inhibiting ALK- mediated signaling for this often-devastating childhood cancer. ..